Ricardo Fernandes1, Sasha Mazzarello2, Habeeb Majeed3, Stephanie Smith2, Risa Shorr4, Brian Hutton5, Mohammed Fk Ibrahim1, Carmel Jacobs1, Michael Ong1, Mark Clemons6,7,8. 1. Division of Medical Oncology, Department of Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, Ontario, Canada. 2. Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario, Canada. 3. Division of Internal Medicine, Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada. 4. The Ottawa Hospital, Ottawa, Ontario, Canada. 5. Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada. 6. Division of Medical Oncology, Department of Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, Ontario, Canada. mclemons@toh.on.ca. 7. Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario, Canada. mclemons@toh.on.ca. 8. Division of Medical Oncology, The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, Canada. mclemons@toh.on.ca.
Abstract
BACKGROUND: Taxane acute pain syndrome (TAPS) is characterized by myalgias and arthralgias starting 1-3 days and lasting 5-7 days after taxane-based chemotherapy. Despite negatively impacting patient's quality of life, little is known about the optimal TAPS management. A systematic review of treatment strategies for TAPS across all tumor sites was performed. METHODS: Embase, Ovid MEDLINE(R), and the Cochrane Central Register of Controlled Trials were searched from 1946 to October 2014 for trials reporting the effectiveness of different treatments of TAPS in cancer patients receiving taxane-based chemotherapy. Two individuals independently screened citations and full-text articles for eligibility. Outcome measures included type of treatment and response of myalgias, arthralgias, pain, and quality of life (QoL). RESULTS: Of 1614 unique citations initially identified, five studies met the pre-specified eligibility criteria. Two were randomized placebo-controlled trials (225 patients), two were randomized open-label trials 76 patients), and one was a retrospective study (10 patients). The agents investigated included gabapentin, amifostine, glutathione, and glutamine. Study sizes ranged from 10 to 185 patients. Given the heterogeneity of study designs, a narrative synthesis of results was performed. Neither glutathione (QoL, p = 0.30, no 95 % CI reported) nor glutamine (mean improvement in average pain was 0.8 in both treatment arms, p = 0.84, no 95 % CI reported) were superior to placebo. Response to amifostine (pain response) and gabapentin (reduction in taxane-induced arthralgias and myalgias) was 36 % (95 % CI, 16-61 %) and 90 % (no 95 % CI data reported), respectively. CONCLUSIONS: Despite its prevalence in patients receiving taxane-based chemotherapies, TAPS remains poorly researched and few studies evaluate its optimal management. If the management of patients is to be improved, more prospective trials are needed.
BACKGROUND:Taxaneacute pain syndrome (TAPS) is characterized by myalgias and arthralgias starting 1-3 days and lasting 5-7 days after taxane-based chemotherapy. Despite negatively impacting patient's quality of life, little is known about the optimal TAPS management. A systematic review of treatment strategies for TAPS across all tumor sites was performed. METHODS: Embase, Ovid MEDLINE(R), and the Cochrane Central Register of Controlled Trials were searched from 1946 to October 2014 for trials reporting the effectiveness of different treatments of TAPS in cancerpatients receiving taxane-based chemotherapy. Two individuals independently screened citations and full-text articles for eligibility. Outcome measures included type of treatment and response of myalgias, arthralgias, pain, and quality of life (QoL). RESULTS: Of 1614 unique citations initially identified, five studies met the pre-specified eligibility criteria. Two were randomized placebo-controlled trials (225 patients), two were randomized open-label trials 76 patients), and one was a retrospective study (10 patients). The agents investigated included gabapentin, amifostine, glutathione, and glutamine. Study sizes ranged from 10 to 185 patients. Given the heterogeneity of study designs, a narrative synthesis of results was performed. Neither glutathione (QoL, p = 0.30, no 95 % CI reported) nor glutamine (mean improvement in average pain was 0.8 in both treatment arms, p = 0.84, no 95 % CI reported) were superior to placebo. Response to amifostine (pain response) and gabapentin (reduction in taxane-induced arthralgias and myalgias) was 36 % (95 % CI, 16-61 %) and 90 % (no 95 % CI data reported), respectively. CONCLUSIONS: Despite its prevalence in patients receiving taxane-based chemotherapies, TAPS remains poorly researched and few studies evaluate its optimal management. If the management of patients is to be improved, more prospective trials are needed.
Authors: I Kuchuk; N Bouganim; K Beusterien; J Grinspan; L Vandermeer; S Gertler; S F Dent; X Song; R Segal; S Mazzarello; F Crawley; G Dranitsaris; M Clemons Journal: Breast Cancer Res Treat Date: 2013-10-16 Impact factor: 4.872
Authors: Alexis D Leal; Rui Qin; Pamela J Atherton; Paul Haluska; Robert J Behrens; Charles H Tiber; Patanit Watanaboonyakhet; Matthias Weiss; Paul T Adams; Travis J Dockter; Charles L Loprinzi Journal: Cancer Date: 2014-03-11 Impact factor: 6.860
Authors: Miguel Martin; Tadeusz Pienkowski; John Mackey; Marek Pawlicki; Jean-Paul Guastalla; Charles Weaver; Eva Tomiak; Taher Al-Tweigeri; Linnea Chap; Eva Juhos; Raymond Guevin; Anthony Howell; Tommy Fornander; John Hainsworth; Robert Coleman; Jeferson Vinholes; Manuel Modiano; Tamas Pinter; Shou C Tang; Bruce Colwell; Catherine Prady; Louise Provencher; David Walde; Alvaro Rodriguez-Lescure; Judith Hugh; Camille Loret; Matthieu Rupin; Sandra Blitz; Philip Jacobs; Michael Murawsky; Alessandro Riva; Charles Vogel Journal: N Engl J Med Date: 2005-06-02 Impact factor: 91.245
Authors: Charles L Loprinzi; Brandi N Reeves; Shaker R Dakhil; Jeff A Sloan; Sherry L Wolf; Kelli N Burger; Arif Kamal; Nguyet A Le-Lindqwister; Gamini S Soori; Anthony J Jaslowski; Paul J Novotny; Daniel H Lachance Journal: J Clin Oncol Date: 2011-03-07 Impact factor: 44.544
Authors: Roy E Smith; Stewart J Anderson; Ann Brown; Aaron P Scholnik; Ajit M Desai; Carl G Kardinal; Barry C Lembersky; Eleftherios P Mamounas Journal: Clin Breast Cancer Date: 2002-12 Impact factor: 3.225
Authors: Byoung Yong Shim; Chi Hong Kim; So Hyang Song; Meyung Im Ahn; Eun Jung Hong; Sung Whan Kim; Suzy Kim; Min Seop Jo; Deog Gon Cho; Kyu Do Cho; Jinyoung Yoo; Hoon-Kyo Kim Journal: Cancer Res Treat Date: 2005-12-31 Impact factor: 4.679
Authors: Nicholas Chiu; Liying Zhang; Rebecca Dent; Angie Giotis; Jenna van Draanen; Daniela Gallo-Hershberg; Leonard Chiu; Ronald Chow; Bo Angela Wan; Mark Pasetka; Jordan Stinson; Erica Stacey; Sunil Verma; Henry Lam; Edward Chow; Carlo DeAngelis Journal: Support Care Cancer Date: 2017-07-22 Impact factor: 3.603
Authors: Mark Clemons; Demetrios Simos; Marta Sienkiewicz; Terry Ng; Labib Zibdawi; Bassam Basulaiman; Arif Awan; Dean Fergusson; Lisa Vandermeer; Deanna Saunders; Brian Hutton; Eitan Amir Journal: Support Care Cancer Date: 2021-03-19 Impact factor: 3.603
Authors: R Fernandes; S Mazzarello; A A Joy; G R Pond; J Hilton; M F K Ibrahim; C Canil; M Ong; C Stober; L Vandermeer; B Hutton; M da Costa; S Damaraju; Mark Clemons Journal: Support Care Cancer Date: 2018-03-21 Impact factor: 3.603
Authors: Ricardo Fernandes; Sasha Mazzarello; Brian Hutton; Risa Shorr; Habeeb Majeed; Mohammed Fk Ibrahim; Carmel Jacobs; Michael Ong; Mark Clemons Journal: Support Care Cancer Date: 2016-05-05 Impact factor: 3.603
Authors: John Hilton; Lisa Vandermeer; Marta Sienkiewicz; Sasha Mazzarello; Brian Hutton; Carol Stober; Dean Fergusson; Phillip Blanchette; Anil A Joy; A Brianne Bota; Mark Clemons Journal: Support Care Cancer Date: 2018-02-06 Impact factor: 3.603